Recent Company News

• 07:52 PM ET Jan 11, 2026
  

  StreetAccount Summary - Trading higher/lower: Australia & New Zealand midday

• 04:43 PM ET Feb 01, 2026
  

  Clinuvel Pharmaceuticals issues outlook in presentation; CUV105 vitiligo top line results expected in 2H26 (A$11.00, 0.00)

• 04:46 PM ET Jan 11, 2026
  

  Clinuvel Pharmaceuticals commences dosing in latest preclinical study with VLRX-L (A$12.64, 0.00)

• 05:50 PM ET Jan 07, 2026
  

  New clinical reports from four patients enrolled in CLINUVEL's ongoing study of SCENESSE (afamelanotide 16Mg) in vitiligo (CUV105) presented at RDTC conference (A$12.26, 0.00)

• 04:45 PM ET Dec 18, 2025
  

  Clinuvel Pharmaceuticals files draft registration statement with U.S. SEC to uplisting ADR program on the Nasdaq (A$12.60, 0.00)